SB 302 Modifies provisions regarding medications, the regulation of food production, and contracts between health carriers and optometrists
Sponsor: Wasson
LR Number: 1531S.02P Fiscal Note available
Committee: Financial and Governmental Organizations and Elections
Last Action: 5/17/2013 - S Calendar S Bills with H Amendments--SCS for SB 302-Wasson, with HA 1, HA 2, HA 3 & HA 4 Journal Page:
Title: SCS SB 302 Calendar Position:
Effective Date: August 28, 2013
House Handler: Elmer

Full Bill Text | All Actions | Amendments/CCRs/CCSs | Available Summaries | Senate Home Page | List of 2013 Senate Bills

Current Bill Summary


SCS/SB 302 - This act allows a pharmacist to dispense an emergency supply of medication without prior authorization from the prescriber in certain situations. The act provides that the pharmacist is to promptly notify the prescriber of the emergency dispensing.

JESSCIA BAKER

HA 1 - THE AMENDMENT ESTABLISHES THE MISSOURI ORAL CHEMOTHERAPY PARITY INTERIM COMMITTEE TO STUDY THE DISPARITY IN PATIENT CO-PAYMENTS BETWEEN ORALLY AND INTRAVENOUSLY ADMINISTERED CHEMOTHERAPIES, THE REASONS FOR THE DISPARITY, AND THE PATIENT BENEFITS IN ESTABLISHING CO-PAYMENT PARITY BETWEEN ORAL AND INFUSED CHEMOTHERAPY AGENTS.

THIS AMENDMENT IS SUBSTANTIALLY SIMILAR TO HCS/HB 593 & 695 (2013).

HA 2 - THE AMENDMENT PROHIBITS A CONTRACT BETWEEN A HEALTH CARRIER OR HEALTH BENEFIT PLAN AND AN OPTOMETRIST FROM REQUIRING THE OPTOMETRIST TO PROVIDE SERVICES TO AN INSURED AT A FEE ESTABLISHED BY THE CARRIER OR PLAN IF THE SERVICES ARE NOT COVERED UNDER THE PLAN.

THIS AMENDMENT IS IDENTICAL TO HB 750 (2013).

HA 3 - THIS AMENDMENT ALLOWS A NONPROFIT ORGANIZATION TO PREPARE FOOD IN A PRIVATE HOME OR OTHER AREA FOR DISTRIBUTION AT A CHARITABLE FUNDRAISING EVENT WITHOUT BEING SUBJECT TO REGULATION OR INSPECTION.

THIS AMENDMENT IS IDENTICAL TO SS/SCS/SB 432 (2013).

HA 4 - THE AMENDMENT PROVIDES THAT WHEN DETERMINING WHETHER A HEALTH CARE PROVIDER HAS REQUESTED AN EXCESSIVE CHARGE FOR A REPACKAGED DRUG, A CHARGE EXCEEDING THE ORIGINAL MANUFACTURER'S AWP FOR SUCH REPACKAGED DRUGS SHALL BE DEEM EXCESSIVE.